Clinical Trial Update: A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial evaluating BIND-014, a docetaxel nanoparticle formulation, in patients with metastatic castration-resist…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• BIND-014 (docetaxel nanoparticle)

Snippet

Sponsor: BIND Therapeutics | Conditions: CRPC, Prostate Cancer | Phase 2 | Status: COMPLETED